Gilead Bets on Hepatitis C Data to Back Pharmasset Deal

Gilead Sciences, after paying $10.8 billion for the developer of an experimental hepatitis C drug, will soon give investors a better sense of whether its largest-deal ever is going to pay off.
Bloomberg